From CNBC:

Demand for weight loss drugs like Wegovy is high in the U.S. despite limited insurance coverage and high costs. A survey by Evercore ISI found that individuals with higher annual incomes are willing to pay more out of pocket for GLP-1 medications. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular choices.
Participants in the survey revealed that those with higher incomes are willing to pay more out of pocket for GLP-1 medications, while those with lower incomes are more price-sensitive. The survey also highlighted concerns about equity in access to these breakthrough drugs due to sparse insurance coverage. Novo Nordisk and Eli Lilly offer savings programs to help reduce costs for weight loss drugs.
People currently taking GLP-1 medications are generally paying $50 or less out of pocket per month. However, some individuals paid over $750 per month. Concerns about premature stoppage due to various reasons, including cost, weight loss goal achievements, and side effects, were raised among insurers. Despite this, many participants intend to stay on the drugs permanently to achieve their weight loss goals.
Survey participants indicated that they would restart taking a GLP-1 if they regain weight after stopping the drug. While some individuals regained weight after stopping treatment, others stayed at a lower weight. GLP-1 medications have been shown to influence eating less and drinking less alcohol among respondents. Studies have shown that certain GLP-1s can curb alcohol intake, but more research is needed in humans.



Read more at CNBC: How much people are willing to spend